Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

Salvatore Del Prete; Liliana Montella; Michele Caraglia; Luigi Maiorino; Gregorio Cennamo; Vincenzo Montesarchio; Guido Piai; Antonio Febbraro; Luciano Tarantino; Elena Capasso

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

【24h】

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

机译：索拉非尼加奥曲肽是晚期肝细胞癌的有效且安全的治疗方法：多中心II期So.LAR。研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in this setting with conflicting results. Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity.

机译：目的不适合局部治疗的晚期肝细胞癌（HCC）治愈的机会有限。索拉非尼是一种多激酶抑制剂，在晚期HCC中具有公认的活性。在这种情况下使用奥曲肽会产生矛盾的结果。在晚期HCC中对索拉非尼和长效奥曲肽治疗进行了评估，以评估安全性和活性。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2010年第5期|p.837-844|共8页
作者
Salvatore Del Prete; Liliana Montella; Michele Caraglia; Luigi Maiorino; Gregorio Cennamo; Vincenzo Montesarchio; Guido Piai; Antonio Febbraro; Luciano Tarantino; Elena Capasso;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Sorafenib; Long; acting octreotide; Hepatocellular carcinoma;

机译：索拉非尼;长效奥曲肽;肝细胞癌;

相似文献

外文文献
中文文献
专利

1. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. [J] . Prete SD, Montella L, Caraglia M, Cancer chemotherapy and pharmacology. . 2010,第5期

机译：索拉非尼加奥曲肽是晚期肝细胞癌的有效且安全的治疗方法：多中心II期So.LAR。研究。
2. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study [J] . Vichien SRIMUNINNIMIT, Virote SRIURANPONG Suthida SUWANVECHO Asia-Pacific journal of clinical oncology . 2014,第3期

机译：索拉非尼联合吉西他滨治疗晚期肝细胞癌的疗效和安全性：一项多中心，开放标签，单组II期研究
3. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11) [J] . Retz Margitta, Bedke Jens, Boegemann Martin, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Switch II：III期随机，顺序，开放标签研究，以评估Sorafenib-Pazopanib对Pazopanib-Sorafenib的疗效和安全性在治疗晚期或转移性肾细胞癌（Auo 33/11）中的疗效和安全性
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Poly(lactide-co-glycolide) Microspheres for Localized, Magnetic Resonance Imaging Monitored, Transcatheter Delivery of Sorafenib to Hepatocellular Carcinoma. [D] . Chen, Jeane. 2015

机译：聚（丙交酯-共-乙交酯）微球体用于局部监测，磁共振成像监测，索拉非尼经导管输送至肝细胞癌。
6. A multicentre open-label phase-I/randomised phase-II study to evaluate safety pharmacokinetics and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [O] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, 2018

机译：一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
7. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study [O] . Prete, Salvatore Del, Montella, Liliana, Caraglia, Michele, 2009

机译：索拉非尼加奥曲肽是晚期肝细胞癌的有效且安全的治疗方法：多中心II期So.LAR。研究

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

摘要

著录项

相似文献

相关主题

期刊订阅